Literature DB >> 29942200

Bladder Cancer Academy 2018 Selected Summaries.

Nermarie Velázquez1.   

Abstract

Entities:  

Keywords:  Immunotherapy; Intravesical chemotherapy; Renal masses; Transurethral resection of a bladder tumor (TURBT); Trimodal therapy (TMT); Urinary biomarkers

Year:  2018        PMID： 29942200      PMCID： PMC6003302          DOI： 10.3909/riu02001BCA

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  33 in total

1.  An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.

Authors:  Vignesh T Packiam; Donald L Lamm; Daniel A Barocas; Andrew Trainer; Benjamin Fand; Ronald L Davis; William Clark; Michael Kroeger; Igor Dumbadze; Karim Chamie; A Karim Kader; Dominic Curran; John Gutheil; Arthur Kuan; Alex W Yeung; Gary D Steinberg
Journal:  Urol Oncol       Date:  2017-07-26       Impact factor: 3.498

2.  Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.

Authors:  Ashish M Kamat; Rian J Dickstein; Fabrizio Messetti; Roosevelt Anderson; Shanna M Pretzsch; Graciela Noguera Gonzalez; Ruth L Katz; Abha Khanna; Tanweer Zaidi; Xifeng Wu; H Barton Grossman; Colin P Dinney
Journal:  J Urol       Date:  2012-01-15       Impact factor: 7.450

3.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors:  D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

4.  National treatment trends among older patients with T1-localized renal cell carcinoma.

Authors:  Simon P Kim; Cary P Gross; Neal Meropol; Alexander Kutikov; Marc C Smaldone; Nilay D Shah; James B Yu; Sarah Psutka; Jonathon Kiechle; Robert Abouassaly
Journal:  Urol Oncol       Date:  2016-11-10       Impact factor: 3.498

5.  Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Authors:  Shahrokh F Shariat; Jose A Karam; Yair Lotan; Pierre I Karakiewizc
Journal:  Rev Urol       Date:  2008

6.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2013-01-09       Impact factor: 41.316

7.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Thomas Powles; Ignacio Durán; Michiel S van der Heijden; Yohann Loriot; Nicholas J Vogelzang; Ugo De Giorgi; Stéphane Oudard; Margitta M Retz; Daniel Castellano; Aristotelis Bamias; Aude Fléchon; Gwenaëlle Gravis; Syed Hussain; Toshimi Takano; Ning Leng; Edward E Kadel; Romain Banchereau; Priti S Hegde; Sanjeev Mariathasan; Na Cui; Xiaodong Shen; Christina L Derleth; Marjorie C Green; Alain Ravaud
Journal:  Lancet       Date:  2017-12-18       Impact factor: 79.321

8.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

9.  Urine-based assays for the detection of bladder cancer.

Authors:  Patrick Villicana; Bryant Whiting; Steve Goodison; Charles J Rosser
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

10.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.

Authors:  Padmanee Sharma; Margaret K Callahan; Petri Bono; Joseph Kim; Pavlina Spiliopoulou; Emiliano Calvo; Rathi N Pillai; Patrick A Ott; Filippo de Braud; Michael Morse; Dung T Le; Dirk Jaeger; Emily Chan; Chris Harbison; Chen-Sheng Lin; Marina Tschaika; Alex Azrilevich; Jonathan E Rosenberg
Journal:  Lancet Oncol       Date:  2016-10-09       Impact factor: 41.316
View more
  2 in total

1.  Preserving Independent Urology: LUGPA's First Decade.

Authors:  Neal D Shore; Deepak A Kapoor; Evan R Goldfischer; David C Chaikin; Earl L Walz; R Jonathan Henderson; Richard G Harris; Robert D Asinof; Gary M Kirsh
Journal:  Rev Urol       Date:  2019

Review 2.  Making Sense of the Epigenome Using Data Integration Approaches.

Authors:  Emma Cazaly; Joseph Saad; Wenyu Wang; Caroline Heckman; Miina Ollikainen; Jing Tang
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.